https://www.selleckchem.com/pr....oducts/ly2880070.htm
BACKGROUND Mutations in the human telomerase reverse transcriptase (hTERT) gene promoter have been reported in hepatocellular carcinoma (HCC); however, analyses of these mutations in liquid biopsies have been technically difficult because of the high GC content of the regions of interest within this promoter. We evaluated the feasibility and prognostic value of hTERT promoter mutations identified in circulating cell-free DNA (cfDNA) from the serum of patients with HCC. OBJECTIVE A cohort of HCC patients (n = 36) who were curatively tr
Like
Comment
Share
